Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million , up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2022-- Aerie Pharmaceuticals, Inc.
Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced
Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment 1 Adds Rocklatan ® and Rhopressa ® , and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770
